Flipper, it is all about PDL-1 expression by the cancers, MRK was more selective with their patient selection and thus limited the breadth of their indications. BMS went for all patients regardless of how much PDL-1 their tumors expressed and that diluted the efficacy measures.
Market Data 
Markets 
AI
